Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Phase 2

Recruiting

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Low Dose PF-07328948
Drug: Medium Dose PF-07328948
Drug: High Dose PF-07328948

First Posted Date: 2025-05-27

Last Posted Date: 2025-07-02

Lead Sponsor: Pfizer

Target Recruit Count: 620

Registration Number: NCT06991257

Locations: 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇯🇵
Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan
🇯🇵
Sagamihara Kyodo Hospital, Sagamihara, Kanagawa, Japan

and more 1 locations

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Phase 2

Not yet recruiting

Conditions: Cachexia
Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: ponsegromab
Drug: placebo

First Posted Date: 2025-05-25

Last Posted Date: 2025-06-29

Lead Sponsor: Pfizer

Target Recruit Count: 982

Registration Number: NCT06989437

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: PF-07275315
Other: Placebo

First Posted Date: 2025-05-18

Last Posted Date: 2025-06-15

Lead Sponsor: Pfizer

Target Recruit Count: 252

Registration Number: NCT06977581

Locations: 🇺🇸
Antelope Valley Clinical Trials, Lancaster, California, United States
🇺🇸
OK Clinical Research, Edmond, Oklahoma, United States
🇺🇸
Premier Research Center, LLC, Hendersonville, Tennessee, United States

and more 13 locations

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Phase 1

Recruiting

Conditions: Carcinoma, Non Small Cell Lung
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Carcinoma, Pancreatic Ductal
Malignant Melanoma

Interventions: Drug: PF-08046037
Drug: sasanlimab

First Posted Date: 2025-05-16

Last Posted Date: 2025-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 399

Registration Number: NCT06974734

Locations: 🇵🇷
Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico
🇺🇸
START Midwest, Grand Rapids, Michigan, United States

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Phase 1

Not yet recruiting

Conditions: Breast Cancer
Breast Neoplasms

Interventions: Drug: Disitamab vedotin

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-11

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT06966453

A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy

Interventions: Biological: PF-07999415
Drug: Placebo

First Posted Date: 2025-05-11

Last Posted Date: 2025-06-29

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT06965465

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Not yet recruiting

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: Ibrance

First Posted Date: 2025-05-08

Last Posted Date: 2025-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 1000

Registration Number: NCT06962969

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Active, not recruiting

Conditions: Metastatic HER2+ Advanced Breast Cancer

Interventions: Drug: Tucatinib
Drug: Trastuzumab
Drug: Capecitabine

First Posted Date: 2025-05-07

Last Posted Date: 2025-06-13

Lead Sponsor: Pfizer

Target Recruit Count: 93

Registration Number: NCT06961331

Locations: 🇺🇸
Pfizer, New York, New York, United States

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

Phase 4

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: TIVDAK

First Posted Date: 2025-05-01

Last Posted Date: 2025-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT06952660

Locations: 🇺🇸
Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States
🇺🇸
Trials365, LLC, Shreveport, Louisiana, United States
🇺🇸
Willis Knighton Cancer Center, Shreveport, Louisiana, United States

and more 4 locations

A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

Active, not recruiting

Conditions: COVID-19 SARS-CoV-2 Infection
COVID-19
COVID-19 Infection
Coronavirus Disease 2019 (COVID-19)
COVID-19 (Coronavirus Disease 2019)
COVID-19 Vaccination
COVID-19 Vaccines
SARS-CoV-2 Infection, COVID19
SARS-CoV-2 Infection, COVID-19

Interventions: Drug: BNT162b2

First Posted Date: 2025-04-11

Last Posted Date: 2025-06-29

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06923137

Locations: 🇺🇸
Pfizer, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy